b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29421659</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>03</Month>\n            <Day>23</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>03</Month>\n            <Day>23</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1090-2104</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>497</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>02</Month>\n                        <Day>26</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Biochemical and biophysical research communications</Title>\n                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>RIP2 enhances cell survival by activation of NF-\xc4\xb8B in triple negative breast cancer cells.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>115-121</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(18)30254-7</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2018.02.034</ELocationID>\n            <Abstract>\n                <AbstractText>Receptor-interacting protein 2 (RIP2) is an essential mediator of inflammation and innate immunity, but little is known about its role outside the immune system. Recently, RIP2 has been linked to chemoresistance of triple negative breast cancer (TNBC), the most aggressive breast cancer subtype for which there is an urgent need for targeted therapies. In this study we show that high expression of RIP2 in breast tumors correlates with a worse prognosis and a higher risk of recurrence. We also demonstrate that RIP2 confers TNBC cell resistance against paclitaxel and ceramide-induced apoptosis. Overexpression of RIP2 lead to NF-\xce\xbaB activation, which contributed to higher expression of pro-survival proteins and cell survival. Conversely, RIP2 knockdown inhibited NF-\xce\xbaB signaling, reduced levels of anti-apoptotic proteins and sensitized cells to drug treatment. Together, these data show that RIP2 promotes survival of breast cancer cells through NF-\xce\xbaB activation and that targeting RIP2 may be therapeutically beneficial for treatment of TNBC.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2018. Published by Elsevier Inc.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Jaafar</LastName>\n                    <ForeName>Rola</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Apoptosis Research Centre, National University of Ireland Galway, Ireland; Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mnich</LastName>\n                    <ForeName>Katarzyna</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Apoptosis Research Centre, National University of Ireland Galway, Ireland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Dolan</LastName>\n                    <ForeName>Sarah</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Apoptosis Research Centre, National University of Ireland Galway, Ireland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hillis</LastName>\n                    <ForeName>Jennifer</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Apoptosis Research Centre, National University of Ireland Galway, Ireland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Almanza</LastName>\n                    <ForeName>Aitor</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Apoptosis Research Centre, National University of Ireland Galway, Ireland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Logue</LastName>\n                    <ForeName>Susan E</ForeName>\n                    <Initials>SE</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Apoptosis Research Centre, National University of Ireland Galway, Ireland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Samali</LastName>\n                    <ForeName>Afshin</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Apoptosis Research Centre, National University of Ireland Galway, Ireland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gorman</LastName>\n                    <ForeName>Adrienne M</ForeName>\n                    <Initials>AM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Apoptosis Research Centre, National University of Ireland Galway, Ireland. Electronic address: Adrienne.gorman@nuigalway.ie.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>02</Month>\n                <Day>06</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>\n            <NlmUniqueID>0372516</NlmUniqueID>\n            <ISSNLinking>0006-291X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D002518">Ceramides</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.1</RegistryNumber>\n                <NameOfSubstance UI="C506253">RIPK2 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.1</RegistryNumber>\n                <NameOfSubstance UI="D053475">Receptor-Interacting Protein Serine-Threonine Kinase 2</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>P88XT4IS4D</RegistryNumber>\n                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002470" MajorTopicYN="Y">Cell Survival</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002518" MajorTopicYN="N">Ceramides</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D053475" MajorTopicYN="N">Receptor-Interacting Protein Serine-Threonine Kinase 2</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Apoptosis</Keyword>\n            <Keyword MajorTopicYN="Y">NF-\xce\xbaB (Nuclear Factor \xce\xba-light-chain-enhancer of activated B cells)</Keyword>\n            <Keyword MajorTopicYN="Y">RIP2 (Receptor-interacting serine-threonine kinase-2)</Keyword>\n            <Keyword MajorTopicYN="Y">TNBC (Triple negative breast cancer)</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>01</Month>\n                <Day>30</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>02</Month>\n                <Day>04</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>2</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>3</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>2</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29421659</ArticleId>\n            <ArticleId IdType="pii">S0006-291X(18)30254-7</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.bbrc.2018.02.034</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'